Expansion in pharmaceutical logistics Sinopharm's recent contracts with Lakeside in China's pharmaceutical logistics market indicate potential for further collaboration and business opportunities in the distribution of critical medicines.

Pioneering mRNA treatments in China China's drive into mRNA treatments, accelerated by the pandemic, presents a significant sales opportunity for Sinopharm as they delve into innovative treatment solutions for various diseases beyond Covid-19.

Global approval of Sinopharm's vaccines Approval of Sinopharm's COVID-19 vaccine by the WHO opens up sales avenues in global markets, particularly in regions where access to vaccines is crucial, presenting opportunities for expansion and growth.

Diversification into underowned assets Sinopharm's move to diversify into under-owned asset classes suggests a potential for unique sales opportunities and market penetration beyond traditional pharmaceutical avenues, enabling business growth and resilience.

Transfer of assets and vaccine companies Sinopharm's transfer of vaccine companies and assets to strategic partners signifies potential sales opportunities in collaborations and joint ventures, paving the way for expanded offerings and increased market presence.